Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-03-27 Major Shareholding Noti…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Zawiadomienie art. 69 Trigon Investment
Major Shareholding Notification Classification · 91% confidence The document is a shareholder notification filed under Polish public offering law (art. 69) detailing the direct shareholding change (loan of 401,956 shares) by an entity, clearly reporting a significant change in major shareholding percentages. This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-03-27 Polish
Zawiadomienie art.69 PAAN Capital
Major Shareholding Notification Classification · 90% confidence The document is a Polish shareholder notification under Article 69 of the Offer Act, detailing the shareholding position before and after an event, with percentages of ownership and voting rights. This is a disclosure of change in significant shareholding levels rather than financial results, management changes, or a general regulatory announcement. It fits the ‘Major Shareholding Notification’ category.
2026-03-27 Polish
Zawiadomienia o zmianie udziału w ogólnej liczby głosów w PolTREG S.A. - Content (PL)
Major Shareholding Notification Classification · 91% confidence The document is a current report in Polish informing about notifications from PAAN Capital and Trigon Investment Banking regarding changes in their proportion of voting rights resulting from a share lending agreement. This aligns with a Major Shareholding Notification where significant shareholders notify threshold crossings. Therefore, it is classified as MRQ.
2026-03-27 Polish
Zawiadomienie art. 19 ust. 3 MAR PAAN Capital
Director's Dealing Classification · 90% confidence The document is a notification under Article 19 of the EU Market Abuse Regulation (MAR) detailing a transaction in the issuer’s shares by a person closely related to management (a loan of 401,956 shares at 0.00 PLN on 27 March 2026). It fits the definition of a Director’s Dealing/insider transaction disclosure rather than a corporate repurchase or financial report. Thus, it should be classified as a Director’s Dealing (DIRS).
2026-03-27 Polish
Powiadomienie od PAAN Capital o transakcji na akcjach Spółki otrzymane w trybie art. 19 MAR - Content (PL)
Regulatory Filings Classification · 75% confidence The document is a brief regulatory notice (“raport bieżący”) by PolTREG S.A. informing the market that it received a notification under MAR Article 19 related to a share loan agreement. It does not contain full financials or management discussion, nor is it an AGM, earnings release, or share issue. It is a mandatory regulatory announcement. The closest classification is Regulatory Filings (RNS).
2026-03-27 Polish
Zakończenie oferty akcji Spółki w ramach procesu przyspieszonej budowy księgi popytu oraz ustalenie ceny emisyjnej akcji nowej emisji serii O - Content (PL)
Share Issue/Capital Change Classification · 92% confidence The document is a Polish “raport bieżący” disclosing the results of an accelerated book building process, including the issuance of new series O shares, pricing, number of shares, and structure of the offer. This constitutes a formal announcement of a share issue/capital change. It is neither an investor presentation nor an earnings release, but rather a regulatory update on share issuance. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-03-27 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.